Sunesis Pharmaceuticals Announces Presentations at 60th American Society of Hematology Annual Meeting
November 01 2018 - 9:17AM
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced two
poster presentations and an oral presentation at the 60th American
Society of Hematology (ASH) Annual Meeting being held December 1-4,
2018 in San Diego, California.
The details for the poster presentations are as
follows:
Date and Time: Saturday,
December 1, 2018, 6:15 PM-8:15 PMAbstract Title:
Vecabrutinib Is Efficacious In Vivo in a Preclinical CLL Adoptive
Transfer ModelSession Number: 642Session
Name: CLL: Therapy, excluding Transplantation: Poster
IPublication Number:
1868Location: San Diego Convention Center, Hall
GH
The full abstract can be viewed here.
Date and Time: Sunday, December
2, 2018, 6:00 PM-8:00 PMAbstract Title:
Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results
from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the
Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor (BTKi),
Vecabrutinib, in B-Lymphoid MalignanciesSession
Number: 642Session Name: CLL: Therapy,
excluding Transplantation: Poster IIPublication
Number: 3141Location: San Diego
Convention Center, Hall GH
The full abstract can be viewed here.
The details for the oral presentation are as
follows:
Date and Time: Monday, December
3, 2018, 7:15 AM (Session runs from 7:00 AM – 8:30
AM)Abstract Title: High Prevalence of BTK
Mutations on Ibrutinib Therapy after 3 Years of Treatment in a
Real-Life Cohort of CLL Patients: A Study from the French
Innovative Leukemia Organization (FILO) GroupSession
Number: 641Session Name: CLL: Biology and
Pathophysiology, excluding Therapy: Mechanisms of Action and
Resistance to Targeted AgentsPublication Number:
584Location: Marriott Marquis San Diego Marina,
Grand Ballroom 5
The full abstract can be viewed here.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing new therapeutics for the treatment of hematologic and
solid cancers. Sunesis has built an experienced drug development
organization committed to improving the lives of people with
cancer. The Company is focused on advancing its novel kinase
inhibitor pipeline, with an emphasis on its oral non-covalent BTK
inhibitor vecabrutinib. Vecabrutinib is currently being evaluated
in a Phase 1b/2 study in adults with chronic lymphocytic leukemia
and other B-cell malignancies that have progressed after prior
therapies. The Company’s proprietary PDK1 inhibitor SNS-510 is in
preclinical development. PDK1 is a master kinase that activates
other kinases important to cell growth and survival including
members of the AKT, PKC, RSK, and SGK families. Sunesis plans to
submit an IND for SNS-510 in 2019. Sunesis is exploring strategic
alternatives for vosaroxin, a late-stage investigational product
for relapsed or refractory AML. Sunesis also has an interest in the
pan-RAF inhibitor TAK-580 which is licensed to Takeda. TAK-580 is
in a clinical trial for pediatric low-grade glioma.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis
Pharmaceuticals, Inc.
This press release contains forward-looking
statements, including statements related to Sunesis’ continued
development of vecabrutinib (SNS-062), including the timing of
Phase 1b/2 trial of vecabrutinib and the therapeutic potential of
vecabrutinib, further development and potential of its kinase
inhibitor pipeline and vosaroxin, and planned development of
SNS-510. Words such as “believe,” “expect,” “look forward,”
“potential,” “will” and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Sunesis' current expectations.
Forward-looking statements involve risks and uncertainties.
Sunesis' actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, the risk related to the timing or
conduct of Sunesis' clinical trials, including the vecabrutinib
Phase 1b/2 trial, the risk that Sunesis' clinical or preclinical
studies for vecabrutinib, SNS-510 or other product candidate may
not demonstrate safety or efficacy or lead to regulatory approval,
the risk that data to date and trends may not be predictive of
future data or results, risks related to the timing or conduct of
Sunesis' clinical trials, that Sunesis' development activities for
vecabrutinib or SNS-510 could be otherwise halted or significantly
delayed for various reasons, that Sunesis may not be able to
receive regulatory approval of vecabrutinib, or SNS-510 in the U.S.
or Europe, and risks related to Sunesis' ability to raise the
capital that it believes to be accessible and is required to fully
finance the development and commercialization of vecabrutinib,
SNS-510 and other product candidates. These and other risk factors
are discussed under "Risk Factors" and elsewhere in Sunesis'
Quarterly Report on Form 10-Q for the quarter ended June 30, 2018
and Sunesis' other filings with the Securities and Exchange
Commission. Sunesis expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein reflect any change in
Sunesis' expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are
based.
Investor and Media Inquiries:Maeve ConneightonArgot
Partners212-600-1902 |
Willie QuinnSunesis Pharmaceuticals
Inc.650-266-3716 |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Apr 2023 to Apr 2024